Christian Sieder
Novartis (Germany)(DE)
Publications by Year
Research Areas
Asthma and respiratory diseases, Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Chronic Obstructive Pulmonary Disease (COPD) Research
Most-Cited Works
- → Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase(2011)355 cited
- → Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks(2018)216 cited
- → Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthma(2008)176 cited
- → Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial(2021)165 cited
- → Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide(2009)153 cited
- → Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study(2019)136 cited
- → Effect of omalizumab on angioedema in H 1 ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ ACT , a randomized controlled trial(2016)128 cited
- → Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study(1999)98 cited
- → Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial(2023)76 cited
- → Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study(2015)69 cited